公开(公告)号：EP2928493A4

公开(公告)日：2017-01-04

申请号：EP13860021

申请日：2013-12-03

申请人： THEVAX GENETICS VACCINE CO LTD

发明人： WU CHIA-MAO ,  CHANG HSIU-KANG

IPC分类号： A61K39/104

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/135 ,  A61K39/17 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K39/385 ,  A61K2039/57 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/21 ,  C07K14/70596 ,  C07K14/81 ,  C07K2319/02 ,  C07K2319/04 ,  C07K2319/095 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/1077 ,  C12N9/14 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2750/10022 ,  C12N2750/10034 ,  C12N2760/18134 ,  C12N2770/24222 ,  C12N2770/24234 ,  C12N2770/24334 ,  C12N2770/32134 ,  C12Y204/02036 ,  C12Y306/05002

摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.

公开(公告)号：EP2928491A4

公开(公告)日：2016-07-13

申请号：EP13860917

申请日：2013-12-03

申请人： THEVAX GENETICS VACCINE CO LTD

发明人： CHOU WEI-I ,  WU CHIA-MAO ,  WU JIUN-MING ,  CHANG HSIU-KANG

IPC分类号： A61K39/104

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/135 ,  A61K39/17 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K39/385 ,  A61K2039/57 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/21 ,  C07K14/70596 ,  C07K14/81 ,  C07K2319/02 ,  C07K2319/04 ,  C07K2319/095 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/1077 ,  C12N9/14 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2750/10022 ,  C12N2750/10034 ,  C12N2760/18134 ,  C12N2770/24222 ,  C12N2770/24234 ,  C12N2770/24334 ,  C12N2770/32134 ,  C12Y204/02036 ,  C12Y306/05002

摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.